Mark W. Brunvand

1.4k total citations
22 papers, 1.2k citations indexed

About

Mark W. Brunvand is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark W. Brunvand has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark W. Brunvand's work include Lymphoma Diagnosis and Treatment (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and HER2/EGFR in Cancer Research (5 papers). Mark W. Brunvand is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and HER2/EGFR in Cancer Research (5 papers). Mark W. Brunvand collaborates with scholars based in United States, Italy and United Kingdom. Mark W. Brunvand's co-authors include Mark Groudine, Anton Krumm, Tea Meulia, John A. Hansen, Patrick Tan, J A Ledbetter, Claudio Anasetti, J Bradshaw, P S Linsley and Jennifer Melrose and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Mark W. Brunvand

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark W. Brunvand United States	15	554	375	293	176	126	22	1.2k
Charles F. Eisenbeis United States	14	820 1.5×	371 1.0×	537 1.8×	247 1.4×	118 0.9×	20	1.3k
Sonja Meixlsperger Germany	11	595 1.1×	228 0.6×	293 1.0×	132 0.8×	106 0.8×	14	918
Erich Piovan Italy	15	327 0.6×	375 1.0×	305 1.0×	147 0.8×	96 0.8×	33	915
José A. Brieva Spain	24	1.0k 1.8×	348 0.9×	187 0.6×	134 0.8×	199 1.6×	45	1.6k
G. Reisbach Germany	16	458 0.8×	258 0.7×	511 1.7×	174 1.0×	156 1.2×	26	1.1k
Anouk Caraux France	11	717 1.3×	258 0.7×	167 0.6×	106 0.6×	179 1.4×	15	1.0k
Joan de Jong Netherlands	10	1.0k 1.8×	494 1.3×	372 1.3×	112 0.6×	100 0.8×	12	1.5k
Agnès Moreau‐Aubry France	17	806 1.5×	448 1.2×	433 1.5×	94 0.5×	108 0.9×	30	1.3k
Giorgio Inghirami United States	16	640 1.2×	231 0.6×	401 1.4×	308 1.8×	102 0.8×	28	1.3k
Liang‐Ji Zhou United States	9	781 1.4×	320 0.9×	205 0.7×	131 0.7×	51 0.4×	10	1.1k

Countries citing papers authored by Mark W. Brunvand

Since Specialization

Citations

This map shows the geographic impact of Mark W. Brunvand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Brunvand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Brunvand more than expected).

Fields of papers citing papers by Mark W. Brunvand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Brunvand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Brunvand. The network helps show where Mark W. Brunvand may publish in the future.

Co-authorship network of co-authors of Mark W. Brunvand

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Brunvand. A scholar is included among the top collaborators of Mark W. Brunvand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Brunvand. Mark W. Brunvand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phillips, Tycel, Mark W. Brunvand, Andy I. Chen, et al.. (2021). Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study. SSRN Electronic Journal.

Brunvand, Mark W. & John M. Carson. (2017). Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD. Hematological Oncology. 36(1). 340–343. 4 indexed citations

Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations

Phillips, Tycel, Mark W. Brunvand, Andy Chen, et al.. (2016). Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. Blood. 128(22). 622–622. 27 indexed citations

Flinn, Ian W., Mark W. Brunvand, Michael Y. Choi, et al.. (2015). Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). Blood. 126(23). 494–494. 24 indexed citations

Casulo, Carla, Julie Vose, William Ho, et al.. (2014). A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. Clinical Immunology. 154(1). 37–46. 18 indexed citations

Flinn, Ian W., Mark W. Brunvand, Martin J.S. Dyer, et al.. (2014). Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood. 124(21). 4687–4687. 22 indexed citations

Advani, Ranjana H., Andy I. Chen, Daniel Lebovic, et al.. (2013). Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL). Blood. 122(21). 4399–4399. 13 indexed citations

Advani, Ranjana H., Daniel Lebovic, Mark W. Brunvand, et al.. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 120(21). 59–59. 11 indexed citations

10.

Barron, Michelle A., Dexiang Gao, Kathryn L. Springer, et al.. (2009). Relationship of Reconstituted Adaptive and Innate Cytomegalovirus (CMV)–Specific Immune Responses with CMV Viremia in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases. 49(12). 1777–1783. 47 indexed citations

11.

Friedberg, Jonathan W., Julie M. Vose, Brad S. Kahl, et al.. (2009). A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.. Blood. 114(22). 3742–3742. 10 indexed citations

12.

Cron, Randy Q., Susan Bort, Yunxia Wang, Mark W. Brunvand, & David B. Lewis. (1999). T Cell Priming Enhances IL-4 Gene Expression by Increasing Nuclear Factor of Activated T Cells. The Journal of Immunology. 162(2). 860–870. 47 indexed citations

13.

Georges, George E., Rainer Storb, Mark W. Brunvand, et al.. (1998). CANINE T CELLS TRANSDUCED WITH A HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE. Transplantation. 66(4). 540–544. 11 indexed citations

14.

Weaver, C H, Finn Bo Petersen, F R Appelbaum, et al.. (1994). High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.. Journal of Clinical Oncology. 12(12). 2559–2566. 52 indexed citations

15.

Weaver, C H, Jack W. Singer, F R Appelbaum, et al.. (1994). Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.. PubMed. 14(5). 813–9. 39 indexed citations

16.

Brunvand, Mark W., Anton Krumm, & Mark Groudine. (1993). In vivofootprinting of the human IL-2 gene reveals a nuclear factor bound to the transcription start site in T cells. Nucleic Acids Research. 21(20). 4824–4829. 28 indexed citations

17.

Tan, Patrick, Claudio Anasetti, John A. Hansen, et al.. (1993). Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1.. The Journal of Experimental Medicine. 177(1). 165–173. 433 indexed citations

18.

Krumm, Anton, Tea Meulia, Mark W. Brunvand, & Mark Groudine. (1992). The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region.. Genes & Development. 6(11). 2201–2213. 235 indexed citations

19.

Brunvand, Mark W., C. B. Collins, Robert B. Livingston, & Ganesh Raghu. (1991). Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer. 67(9). 2407–2409. 29 indexed citations

20.

Brunvand, Mark W., Albrecht Schmidt, & Ulrich Siebenlist. (1988). Nuclear factors interacting with the mitogen-responsive regulatory region of the interleukin-2 gene.. Journal of Biological Chemistry. 263(35). 18904–18910. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact